Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance
Author:
Affiliation:
1. Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
2. Department of Hematology, Fujita Health University School of Medicine
Publisher
Japanese Society for Lymphoreticular Tissue Research
Subject
General Medicine
Link
https://www.jstage.jst.go.jp/article/jslrt/56/2/56_89/_pdf
Reference93 articles.
1. 1 Maloney DG: Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 366:2008-2016, 2012
2. 2 Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, et al.: Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 95:135-143, 2010
3. 3 Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
4. 4 Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, et al.: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 116:2040-2045, 2010
5. 5 Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, et al.: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188-2195, 1997
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics;Frontiers in Immunology;2024-01-17
2. Therapeutic antibodies against cancer—A step toward the treatment;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024
3. Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies;Frontiers in Cell and Developmental Biology;2023-10-31
4. Development of Stable CHO-K1 Cell Lines Overexpressing Full Length Human CD20 Antigen;Iranian Biomedical Journal;2023-09-01
5. Immune-based therapies in diffuse large B-cell lymphoma;Expert Opinion on Investigational Drugs;2023-06-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3